| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Growth Differentiation Factor 2 | 28 | 2024 | 158 | 2.220 |
Why?
|
| Osteogenesis | 31 | 2024 | 264 | 2.180 |
Why?
|
| Cell Differentiation | 46 | 2021 | 1547 | 1.990 |
Why?
|
| Bone Neoplasms | 15 | 2025 | 321 | 1.980 |
Why?
|
| Osteosarcoma | 19 | 2022 | 163 | 1.970 |
Why?
|
| Stem Cells | 16 | 2024 | 380 | 1.190 |
Why?
|
| Cell Proliferation | 31 | 2021 | 1688 | 1.060 |
Why?
|
| Bone Morphogenetic Proteins | 15 | 2016 | 127 | 0.950 |
Why?
|
| Wnt Proteins | 14 | 2017 | 131 | 0.880 |
Why?
|
| Signal Transduction | 32 | 2021 | 3426 | 0.870 |
Why?
|
| Antineoplastic Agents | 13 | 2021 | 2337 | 0.800 |
Why?
|
| beta Catenin | 17 | 2019 | 267 | 0.800 |
Why?
|
| Genetic Vectors | 17 | 2019 | 446 | 0.780 |
Why?
|
| Osteoblasts | 9 | 2013 | 97 | 0.770 |
Why?
|
| Adenoviridae | 18 | 2014 | 349 | 0.720 |
Why?
|
| Mice | 62 | 2024 | 11932 | 0.680 |
Why?
|
| HEK293 Cells | 25 | 2019 | 660 | 0.640 |
Why?
|
| Femoral Neoplasms | 2 | 2017 | 23 | 0.640 |
Why?
|
| Tissue Scaffolds | 5 | 2024 | 119 | 0.630 |
Why?
|
| Wnt Signaling Pathway | 6 | 2021 | 103 | 0.590 |
Why?
|
| Genetic Therapy | 8 | 2014 | 373 | 0.570 |
Why?
|
| Mice, Nude | 23 | 2021 | 819 | 0.570 |
Why?
|
| Retinoid X Receptors | 5 | 2010 | 39 | 0.570 |
Why?
|
| Prophylactic Surgical Procedures | 1 | 2017 | 7 | 0.560 |
Why?
|
| Fracture Fixation, Intramedullary | 1 | 2017 | 13 | 0.560 |
Why?
|
| Tretinoin | 6 | 2012 | 130 | 0.550 |
Why?
|
| Receptors, Retinoic Acid | 6 | 2012 | 48 | 0.540 |
Why?
|
| Animals | 75 | 2024 | 27691 | 0.540 |
Why?
|
| Growth Differentiation Factors | 9 | 2016 | 57 | 0.520 |
Why?
|
| Thromboembolism | 1 | 2017 | 124 | 0.520 |
Why?
|
| Cell Line | 27 | 2021 | 2505 | 0.490 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2017 | 129 | 0.490 |
Why?
|
| Sarcoma, Ewing | 2 | 2014 | 42 | 0.460 |
Why?
|
| Cell Line, Tumor | 21 | 2021 | 2607 | 0.460 |
Why?
|
| PPAR gamma | 4 | 2012 | 73 | 0.440 |
Why?
|
| RNA, Small Interfering | 5 | 2019 | 558 | 0.440 |
Why?
|
| Gene Expression Regulation, Neoplastic | 9 | 2018 | 1286 | 0.430 |
Why?
|
| Humans | 108 | 2025 | 90568 | 0.430 |
Why?
|
| Niclosamide | 3 | 2018 | 10 | 0.410 |
Why?
|
| Cytoskeletal Proteins | 6 | 2004 | 229 | 0.400 |
Why?
|
| Sarcoma | 5 | 2017 | 217 | 0.400 |
Why?
|
| Trans-Activators | 7 | 2004 | 443 | 0.370 |
Why?
|
| Gene Transfer Techniques | 7 | 2014 | 153 | 0.360 |
Why?
|
| Transduction, Genetic | 6 | 2016 | 160 | 0.350 |
Why?
|
| Apoptosis | 10 | 2021 | 1723 | 0.340 |
Why?
|
| Mebendazole | 2 | 2021 | 8 | 0.330 |
Why?
|
| Antinematodal Agents | 2 | 2021 | 9 | 0.330 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2021 | 455 | 0.330 |
Why?
|
| Odontogenesis | 3 | 2021 | 15 | 0.330 |
Why?
|
| Liver | 5 | 2017 | 1216 | 0.330 |
Why?
|
| Tissue Engineering | 2 | 2024 | 196 | 0.320 |
Why?
|
| RNA, Long Noncoding | 2 | 2021 | 120 | 0.320 |
Why?
|
| Drug Synergism | 8 | 2018 | 307 | 0.320 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2013 | 306 | 0.310 |
Why?
|
| S100 Proteins | 3 | 2015 | 52 | 0.300 |
Why?
|
| Hepatocytes | 3 | 2014 | 124 | 0.290 |
Why?
|
| Monensin | 2 | 2018 | 16 | 0.290 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 12 | 2022 | 888 | 0.290 |
Why?
|
| Antigens, Polyomavirus Transforming | 4 | 2018 | 47 | 0.280 |
Why?
|
| RNA Interference | 6 | 2019 | 377 | 0.280 |
Why?
|
| Ovarian Neoplasms | 3 | 2021 | 776 | 0.280 |
Why?
|
| Adipogenesis | 3 | 2021 | 40 | 0.280 |
Why?
|
| Cell Movement | 13 | 2021 | 793 | 0.280 |
Why?
|
| Chondrosarcoma | 3 | 2025 | 50 | 0.270 |
Why?
|
| Gene Expression | 7 | 2019 | 1312 | 0.270 |
Why?
|
| Fibroblasts | 6 | 2018 | 764 | 0.260 |
Why?
|
| Chondrocytes | 4 | 2014 | 65 | 0.250 |
Why?
|
| MicroRNAs | 2 | 2022 | 561 | 0.250 |
Why?
|
| Xenograft Model Antitumor Assays | 7 | 2021 | 491 | 0.250 |
Why?
|
| Spinal Diseases | 1 | 2005 | 44 | 0.250 |
Why?
|
| Bone Regeneration | 4 | 2024 | 65 | 0.250 |
Why?
|
| Piperazines | 2 | 2004 | 284 | 0.250 |
Why?
|
| Real-Time Polymerase Chain Reaction | 5 | 2022 | 285 | 0.240 |
Why?
|
| Nanocomposites | 1 | 2024 | 16 | 0.240 |
Why?
|
| Cell Division | 5 | 2014 | 691 | 0.240 |
Why?
|
| Spinal Fusion | 1 | 2005 | 87 | 0.240 |
Why?
|
| Dental Papilla | 2 | 2014 | 6 | 0.240 |
Why?
|
| Alkaline Phosphatase | 11 | 2021 | 132 | 0.230 |
Why?
|
| Wound Healing | 5 | 2021 | 365 | 0.230 |
Why?
|
| Colorectal Neoplasms | 5 | 2014 | 974 | 0.230 |
Why?
|
| Cell Cycle Proteins | 4 | 2015 | 399 | 0.230 |
Why?
|
| Thiazolidinediones | 2 | 2018 | 74 | 0.230 |
Why?
|
| Pyrimidines | 2 | 2004 | 371 | 0.230 |
Why?
|
| Educational Measurement | 2 | 1998 | 232 | 0.230 |
Why?
|
| Printing, Three-Dimensional | 1 | 2024 | 47 | 0.230 |
Why?
|
| Neoplasm Metastasis | 5 | 2014 | 1066 | 0.220 |
Why?
|
| Bone and Bones | 5 | 2024 | 273 | 0.220 |
Why?
|
| Chondrogenesis | 4 | 2021 | 28 | 0.220 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2014 | 3486 | 0.220 |
Why?
|
| Embryonic Stem Cells | 2 | 2014 | 82 | 0.220 |
Why?
|
| DNA Transposable Elements | 2 | 2014 | 175 | 0.210 |
Why?
|
| Gene Expression Regulation | 7 | 2013 | 1991 | 0.210 |
Why?
|
| Cartilage, Articular | 2 | 2014 | 70 | 0.210 |
Why?
|
| Thiazoles | 2 | 2010 | 127 | 0.210 |
Why?
|
| Cisplatin | 3 | 2021 | 599 | 0.210 |
Why?
|
| Chromans | 1 | 2002 | 29 | 0.200 |
Why?
|
| Achilles Tendon | 2 | 2016 | 16 | 0.200 |
Why?
|
| Genes, Reporter | 10 | 2017 | 274 | 0.200 |
Why?
|
| Ossification, Heterotopic | 2 | 2021 | 34 | 0.200 |
Why?
|
| Cytoplasm | 1 | 2002 | 285 | 0.190 |
Why?
|
| Desmoplastic Small Round Cell Tumor | 1 | 2021 | 6 | 0.190 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2011 | 2702 | 0.190 |
Why?
|
| Histamine H1 Antagonists | 1 | 2001 | 40 | 0.190 |
Why?
|
| Wnt3A Protein | 4 | 2015 | 23 | 0.190 |
Why?
|
| Luciferases | 5 | 2010 | 128 | 0.190 |
Why?
|
| Tooth Germ | 1 | 2021 | 6 | 0.190 |
Why?
|
| Cell Nucleus | 2 | 2002 | 605 | 0.180 |
Why?
|
| Blotting, Western | 7 | 2013 | 794 | 0.180 |
Why?
|
| Clinical Competence | 2 | 1998 | 796 | 0.180 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2021 | 610 | 0.170 |
Why?
|
| Bone Morphogenetic Protein 2 | 5 | 2014 | 48 | 0.170 |
Why?
|
| Neoplasm Staging | 4 | 2014 | 2018 | 0.170 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 3 | 2006 | 182 | 0.170 |
Why?
|
| Transfection | 6 | 2019 | 910 | 0.170 |
Why?
|
| Smad Proteins | 4 | 2013 | 43 | 0.170 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2013 | 565 | 0.170 |
Why?
|
| Cell Survival | 7 | 2016 | 987 | 0.170 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2016 | 44 | 0.170 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2017 | 1096 | 0.170 |
Why?
|
| Male | 26 | 2021 | 42931 | 0.160 |
Why?
|
| Cell Cycle | 5 | 2021 | 511 | 0.160 |
Why?
|
| Transgenes | 3 | 2014 | 185 | 0.160 |
Why?
|
| Ear, External | 1 | 1999 | 26 | 0.160 |
Why?
|
| Osteocytes | 2 | 2012 | 9 | 0.160 |
Why?
|
| Receptors, Notch | 1 | 2019 | 127 | 0.160 |
Why?
|
| ErbB Receptors | 3 | 2018 | 499 | 0.160 |
Why?
|
| Umbilical Cord | 1 | 2018 | 41 | 0.150 |
Why?
|
| Viral Proteins | 2 | 2014 | 303 | 0.150 |
Why?
|
| Cysts | 1 | 1999 | 106 | 0.150 |
Why?
|
| Gene Expression Profiling | 7 | 2017 | 1460 | 0.150 |
Why?
|
| Angiotensin II | 1 | 2018 | 93 | 0.150 |
Why?
|
| Niacinamide | 1 | 2018 | 100 | 0.150 |
Why?
|
| Phenylurea Compounds | 1 | 2018 | 95 | 0.150 |
Why?
|
| Bone Diseases | 2 | 2011 | 58 | 0.150 |
Why?
|
| Cells, Cultured | 11 | 2013 | 2892 | 0.150 |
Why?
|
| Fetus | 3 | 2013 | 232 | 0.140 |
Why?
|
| Female | 24 | 2021 | 46855 | 0.140 |
Why?
|
| Cell Line, Transformed | 5 | 2016 | 154 | 0.140 |
Why?
|
| Cell Self Renewal | 1 | 2017 | 20 | 0.140 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2017 | 14 | 0.140 |
Why?
|
| Fibrosis | 1 | 2018 | 238 | 0.140 |
Why?
|
| Retinoic Acid Receptor alpha | 3 | 2012 | 18 | 0.140 |
Why?
|
| Green Fluorescent Proteins | 9 | 2012 | 309 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2018 | 589 | 0.130 |
Why?
|
| Biomarkers | 8 | 2017 | 1797 | 0.130 |
Why?
|
| Melanocytes | 2 | 2017 | 57 | 0.130 |
Why?
|
| Epidermal Growth Factor | 2 | 2013 | 118 | 0.130 |
Why?
|
| Tenocytes | 1 | 2016 | 4 | 0.130 |
Why?
|
| Promoter Regions, Genetic | 4 | 2014 | 961 | 0.130 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2016 | 115 | 0.130 |
Why?
|
| DNA | 3 | 2014 | 1314 | 0.130 |
Why?
|
| Cell Culture Techniques | 2 | 2018 | 198 | 0.130 |
Why?
|
| Faculty, Medical | 1 | 1998 | 193 | 0.130 |
Why?
|
| Organoplatinum Compounds | 1 | 2015 | 94 | 0.130 |
Why?
|
| Tumor Cells, Cultured | 7 | 2010 | 1049 | 0.120 |
Why?
|
| Anthelmintics | 1 | 2015 | 6 | 0.120 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 229 | 0.120 |
Why?
|
| Phenotype | 5 | 2014 | 2471 | 0.120 |
Why?
|
| Gene Expression Regulation, Developmental | 4 | 2017 | 666 | 0.120 |
Why?
|
| Education, Medical | 1 | 1998 | 244 | 0.120 |
Why?
|
| Role Playing | 1 | 1994 | 1 | 0.120 |
Why?
|
| Orthopedics | 2 | 2025 | 131 | 0.120 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2018 | 333 | 0.120 |
Why?
|
| Simian virus 40 | 1 | 2014 | 35 | 0.120 |
Why?
|
| Hexadimethrine Bromide | 1 | 2014 | 4 | 0.120 |
Why?
|
| Multipotent Stem Cells | 1 | 2014 | 19 | 0.120 |
Why?
|
| Phosphoproteins | 2 | 2014 | 261 | 0.110 |
Why?
|
| Neoplasms | 4 | 2015 | 3029 | 0.110 |
Why?
|
| Virus Assembly | 1 | 2014 | 21 | 0.110 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 2 | 2007 | 122 | 0.110 |
Why?
|
| Immediate-Early Proteins | 2 | 2006 | 164 | 0.110 |
Why?
|
| Mice, Inbred C3H | 6 | 2012 | 371 | 0.110 |
Why?
|
| Estrogen Receptor beta | 1 | 2013 | 25 | 0.110 |
Why?
|
| Fluorescent Dyes | 1 | 2015 | 254 | 0.110 |
Why?
|
| Protein Precursors | 1 | 2014 | 140 | 0.110 |
Why?
|
| Carcinogenesis | 1 | 2015 | 216 | 0.110 |
Why?
|
| Biopsy | 2 | 2021 | 1192 | 0.110 |
Why?
|
| Integrases | 3 | 2014 | 63 | 0.110 |
Why?
|
| Mesoderm | 2 | 2004 | 124 | 0.110 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2013 | 69 | 0.110 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 5 | 1 | 2013 | 7 | 0.110 |
Why?
|
| Receptor Cross-Talk | 1 | 2013 | 33 | 0.110 |
Why?
|
| Patients | 1 | 1994 | 104 | 0.110 |
Why?
|
| Time Factors | 9 | 2014 | 5365 | 0.110 |
Why?
|
| Mutation | 3 | 2010 | 4184 | 0.110 |
Why?
|
| Treatment Outcome | 5 | 2014 | 8373 | 0.110 |
Why?
|
| Kidney Neoplasms | 1 | 2018 | 525 | 0.110 |
Why?
|
| Recombination, Genetic | 3 | 2014 | 446 | 0.110 |
Why?
|
| Tetracycline | 2 | 2004 | 13 | 0.110 |
Why?
|
| Postoperative Complications | 3 | 2017 | 2342 | 0.100 |
Why?
|
| Disease Models, Animal | 5 | 2021 | 2407 | 0.100 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2013 | 128 | 0.100 |
Why?
|
| Gene Knockdown Techniques | 3 | 2021 | 252 | 0.100 |
Why?
|
| Program Evaluation | 1 | 1994 | 311 | 0.100 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 684 | 0.100 |
Why?
|
| Cell Adhesion Molecules | 1 | 2013 | 166 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2013 | 226 | 0.100 |
Why?
|
| Janus Kinase 1 | 1 | 2012 | 16 | 0.100 |
Why?
|
| Estrogen Receptor alpha | 1 | 2013 | 148 | 0.100 |
Why?
|
| Melanoma | 1 | 2017 | 473 | 0.100 |
Why?
|
| STAT Transcription Factors | 1 | 2012 | 18 | 0.100 |
Why?
|
| Biomarkers, Tumor | 3 | 2017 | 1550 | 0.100 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2012 | 43 | 0.100 |
Why?
|
| Cloning, Organism | 1 | 2012 | 19 | 0.100 |
Why?
|
| Head and Neck Neoplasms | 2 | 2017 | 1061 | 0.100 |
Why?
|
| Growth Hormone | 1 | 2012 | 96 | 0.100 |
Why?
|
| HCT116 Cells | 4 | 2019 | 158 | 0.100 |
Why?
|
| Phosphorylation | 4 | 2018 | 1132 | 0.100 |
Why?
|
| Endoplasmic Reticulum | 1 | 2013 | 256 | 0.100 |
Why?
|
| Cell Adhesion | 5 | 2016 | 429 | 0.100 |
Why?
|
| General Surgery | 1 | 1994 | 244 | 0.100 |
Why?
|
| Education, Medical, Undergraduate | 1 | 1994 | 179 | 0.100 |
Why?
|
| Zebrafish Proteins | 2 | 2003 | 151 | 0.090 |
Why?
|
| Culture Media, Conditioned | 5 | 2014 | 103 | 0.090 |
Why?
|
| Pluripotent Stem Cells | 2 | 2009 | 34 | 0.090 |
Why?
|
| Extremities | 3 | 2013 | 176 | 0.090 |
Why?
|
| Immunohistochemistry | 6 | 2017 | 1806 | 0.090 |
Why?
|
| Cell Lineage | 5 | 2012 | 295 | 0.090 |
Why?
|
| Benzylisoquinolines | 1 | 2010 | 3 | 0.090 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2010 | 33 | 0.090 |
Why?
|
| Intestines | 1 | 2014 | 416 | 0.090 |
Why?
|
| DNA Primers | 3 | 2022 | 546 | 0.090 |
Why?
|
| Neoplasm Transplantation | 4 | 2014 | 397 | 0.090 |
Why?
|
| Aged, 80 and over | 4 | 2017 | 6812 | 0.090 |
Why?
|
| Activin Receptors, Type I | 1 | 2010 | 13 | 0.090 |
Why?
|
| CCN Intercellular Signaling Proteins | 1 | 2010 | 3 | 0.090 |
Why?
|
| Transforming Growth Factor beta | 4 | 2007 | 326 | 0.090 |
Why?
|
| Growth and Development | 1 | 2010 | 13 | 0.090 |
Why?
|
| Acyltransferases | 1 | 2010 | 50 | 0.090 |
Why?
|
| Durapatite | 2 | 2024 | 33 | 0.090 |
Why?
|
| Up-Regulation | 5 | 2015 | 728 | 0.090 |
Why?
|
| Osteotomy | 1 | 2010 | 33 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 806 | 0.090 |
Why?
|
| Heart | 1 | 2013 | 580 | 0.090 |
Why?
|
| Bone Transplantation | 1 | 2010 | 68 | 0.080 |
Why?
|
| Tibia | 1 | 2010 | 79 | 0.080 |
Why?
|
| Cloning, Molecular | 2 | 2019 | 646 | 0.080 |
Why?
|
| Ginsenosides | 1 | 2010 | 123 | 0.080 |
Why?
|
| Carrier Proteins | 1 | 2013 | 680 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2014 | 1935 | 0.080 |
Why?
|
| Curriculum | 1 | 1994 | 574 | 0.080 |
Why?
|
| Osteoblastoma | 1 | 2009 | 4 | 0.080 |
Why?
|
| Myoblasts | 1 | 2009 | 32 | 0.080 |
Why?
|
| Base Sequence | 5 | 2014 | 2329 | 0.080 |
Why?
|
| Drug Repositioning | 2 | 2021 | 25 | 0.080 |
Why?
|
| Down-Regulation | 3 | 2010 | 521 | 0.080 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2018 | 219 | 0.080 |
Why?
|
| Neoplastic Stem Cells | 1 | 2010 | 163 | 0.080 |
Why?
|
| DNA Mutational Analysis | 2 | 2017 | 531 | 0.080 |
Why?
|
| Frontal Sinus | 1 | 1988 | 7 | 0.080 |
Why?
|
| Heterografts | 2 | 2021 | 105 | 0.080 |
Why?
|
| Skull Fractures | 1 | 1988 | 26 | 0.080 |
Why?
|
| Glycoproteins | 1 | 2009 | 236 | 0.080 |
Why?
|
| Embryo, Mammalian | 3 | 2014 | 223 | 0.080 |
Why?
|
| Protein Isoforms | 1 | 2009 | 281 | 0.070 |
Why?
|
| Luminescent Proteins | 3 | 2003 | 144 | 0.070 |
Why?
|
| Atlanto-Axial Joint | 1 | 1987 | 9 | 0.070 |
Why?
|
| Bone Development | 1 | 2008 | 37 | 0.070 |
Why?
|
| RNA, Messenger | 3 | 2010 | 2030 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 3 | 2017 | 923 | 0.070 |
Why?
|
| Meningitis | 1 | 1987 | 21 | 0.070 |
Why?
|
| Immunoenzyme Techniques | 2 | 2010 | 303 | 0.070 |
Why?
|
| Aged | 7 | 2017 | 19404 | 0.070 |
Why?
|
| Joint Dislocations | 1 | 1987 | 27 | 0.070 |
Why?
|
| Skin Neoplasms | 1 | 1993 | 600 | 0.070 |
Why?
|
| Prognosis | 2 | 2014 | 3810 | 0.070 |
Why?
|
| Travel | 1 | 2008 | 73 | 0.070 |
Why?
|
| Models, Biological | 4 | 2008 | 1770 | 0.070 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2008 | 177 | 0.070 |
Why?
|
| Calcification, Physiologic | 3 | 2013 | 33 | 0.070 |
Why?
|
| Imatinib Mesylate | 2 | 2004 | 126 | 0.070 |
Why?
|
| Tensile Strength | 1 | 2007 | 83 | 0.070 |
Why?
|
| Retrospective Studies | 3 | 2017 | 9323 | 0.070 |
Why?
|
| Drug Therapy | 1 | 2007 | 69 | 0.070 |
Why?
|
| Hoarseness | 2 | 1998 | 11 | 0.070 |
Why?
|
| Gene Silencing | 3 | 2014 | 178 | 0.070 |
Why?
|
| Adult | 10 | 2017 | 26940 | 0.070 |
Why?
|
| Genetic Engineering | 1 | 2007 | 116 | 0.070 |
Why?
|
| Fellowships and Scholarships | 1 | 2008 | 129 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 3 | 2014 | 570 | 0.070 |
Why?
|
| Transcription Factors | 3 | 2003 | 1673 | 0.070 |
Why?
|
| Disease | 1 | 2007 | 90 | 0.070 |
Why?
|
| Benzamides | 2 | 2004 | 236 | 0.070 |
Why?
|
| X-Ray Microtomography | 2 | 2021 | 93 | 0.060 |
Why?
|
| Middle Aged | 8 | 2017 | 26327 | 0.060 |
Why?
|
| Medical History Taking | 2 | 1998 | 83 | 0.060 |
Why?
|
| Enzyme Inhibitors | 2 | 2013 | 651 | 0.060 |
Why?
|
| Survival Rate | 3 | 2009 | 1899 | 0.060 |
Why?
|
| Transcription, Genetic | 3 | 2008 | 1161 | 0.060 |
Why?
|
| Fracture Healing | 1 | 2005 | 37 | 0.060 |
Why?
|
| Core Binding Factor Alpha 1 Subunit | 3 | 2009 | 23 | 0.060 |
Why?
|
| Tendons | 1 | 2005 | 45 | 0.060 |
Why?
|
| Transcriptional Activation | 2 | 2003 | 295 | 0.060 |
Why?
|
| Citric Acid | 1 | 2024 | 46 | 0.060 |
Why?
|
| Delphi Technique | 1 | 2025 | 105 | 0.060 |
Why?
|
| Urine | 1 | 2024 | 94 | 0.060 |
Why?
|
| Transcriptome | 2 | 2022 | 668 | 0.060 |
Why?
|
| Smad4 Protein | 2 | 2019 | 24 | 0.060 |
Why?
|
| Kidney | 4 | 2018 | 1150 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2016 | 2523 | 0.060 |
Why?
|
| Chemoprevention | 1 | 2004 | 92 | 0.060 |
Why?
|
| Drug Design | 1 | 2004 | 129 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2022 | 2782 | 0.050 |
Why?
|
| Wnt1 Protein | 3 | 2013 | 27 | 0.050 |
Why?
|
| High Mobility Group Proteins | 1 | 2003 | 27 | 0.050 |
Why?
|
| Intervertebral Disc Displacement | 1 | 2003 | 22 | 0.050 |
Why?
|
| Cell Separation | 2 | 2014 | 200 | 0.050 |
Why?
|
| Choristoma | 2 | 2013 | 68 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2008 | 693 | 0.050 |
Why?
|
| Fluorometry | 1 | 2002 | 30 | 0.050 |
Why?
|
| Consensus | 1 | 2025 | 371 | 0.050 |
Why?
|
| Protein Engineering | 1 | 2004 | 145 | 0.050 |
Why?
|
| Muscle Proteins | 1 | 2003 | 132 | 0.050 |
Why?
|
| Cyclin D1 | 1 | 2002 | 84 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2002 | 68 | 0.050 |
Why?
|
| Rabbits | 3 | 2013 | 641 | 0.050 |
Why?
|
| DNA, Recombinant | 1 | 2002 | 67 | 0.050 |
Why?
|
| HT29 Cells | 1 | 2002 | 50 | 0.050 |
Why?
|
| Stem Cell Transplantation | 2 | 2017 | 190 | 0.050 |
Why?
|
| Bone Matrix | 2 | 2013 | 19 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2003 | 665 | 0.050 |
Why?
|
| RNA, Neoplasm | 1 | 2002 | 88 | 0.050 |
Why?
|
| Extracellular Matrix | 2 | 2014 | 248 | 0.050 |
Why?
|
| Flow Cytometry | 2 | 2014 | 694 | 0.050 |
Why?
|
| S100 Calcium Binding Protein A6 | 2 | 2015 | 12 | 0.050 |
Why?
|
| DNA, Neoplasm | 1 | 2002 | 266 | 0.050 |
Why?
|
| Sleep Stages | 1 | 2001 | 47 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2002 | 130 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2013 | 324 | 0.050 |
Why?
|
| Child | 4 | 2010 | 7216 | 0.050 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2021 | 39 | 0.050 |
Why?
|
| Bone Morphogenetic Protein 6 | 3 | 2007 | 10 | 0.050 |
Why?
|
| Plasmids | 1 | 2002 | 292 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 2 | 2014 | 1095 | 0.050 |
Why?
|
| Gene Dosage | 1 | 2002 | 210 | 0.050 |
Why?
|
| Luciferases, Firefly | 2 | 2012 | 12 | 0.050 |
Why?
|
| Drug Costs | 1 | 2001 | 65 | 0.050 |
Why?
|
| Exons | 1 | 2002 | 453 | 0.050 |
Why?
|
| Protein Structure, Tertiary | 3 | 2013 | 742 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 2019 | 0.050 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2021 | 67 | 0.050 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2021 | 133 | 0.050 |
Why?
|
| Femur | 1 | 2021 | 112 | 0.050 |
Why?
|
| Histone Deacetylases | 1 | 2001 | 84 | 0.050 |
Why?
|
| Central Nervous System | 1 | 2001 | 154 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2021 | 99 | 0.040 |
Why?
|
| Neovascularization, Physiologic | 2 | 2012 | 144 | 0.040 |
Why?
|
| Enzyme Activation | 2 | 2013 | 697 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2022 | 270 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2025 | 403 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2022 | 474 | 0.040 |
Why?
|
| Ear Diseases | 1 | 1999 | 20 | 0.040 |
Why?
|
| Neoplasm Proteins | 2 | 2018 | 538 | 0.040 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2018 | 88 | 0.040 |
Why?
|
| Class Ib Phosphatidylinositol 3-Kinase | 1 | 2018 | 4 | 0.040 |
Why?
|
| Transposon Resolvases | 1 | 2018 | 7 | 0.040 |
Why?
|
| Adenocarcinoma | 2 | 2002 | 1182 | 0.040 |
Why?
|
| Psychomotor Performance | 1 | 2001 | 497 | 0.040 |
Why?
|
| Quinoxalines | 1 | 2018 | 50 | 0.040 |
Why?
|
| Pharyngitis | 1 | 1998 | 15 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 478 | 0.040 |
Why?
|
| Microscopy, Fluorescence | 3 | 2004 | 441 | 0.040 |
Why?
|
| Protein Binding | 3 | 2010 | 1500 | 0.040 |
Why?
|
| Deoxycytidine | 1 | 2018 | 212 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 524 | 0.040 |
Why?
|
| Repressor Proteins | 2 | 2016 | 428 | 0.040 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2018 | 120 | 0.040 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2018 | 138 | 0.040 |
Why?
|
| Liver Regeneration | 1 | 2017 | 36 | 0.040 |
Why?
|
| Pancreas | 1 | 2018 | 253 | 0.030 |
Why?
|
| Cognition | 1 | 2001 | 587 | 0.030 |
Why?
|
| Mammals | 1 | 2019 | 245 | 0.030 |
Why?
|
| ets-Domain Protein Elk-1 | 1 | 2016 | 8 | 0.030 |
Why?
|
| Antiparasitic Agents | 1 | 2016 | 8 | 0.030 |
Why?
|
| Transcription Factor AP-1 | 1 | 2016 | 65 | 0.030 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2016 | 53 | 0.030 |
Why?
|
| Acrylic Resins | 1 | 2016 | 23 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2018 | 898 | 0.030 |
Why?
|
| Gelatin | 1 | 2016 | 26 | 0.030 |
Why?
|
| Citrates | 1 | 2016 | 28 | 0.030 |
Why?
|
| Bone Morphogenetic Protein 7 | 2 | 2007 | 13 | 0.030 |
Why?
|
| Observer Variation | 1 | 1998 | 615 | 0.030 |
Why?
|
| Materials Testing | 1 | 2016 | 93 | 0.030 |
Why?
|
| Injections, Intramuscular | 2 | 2007 | 64 | 0.030 |
Why?
|
| DNA Nucleotidyltransferases | 1 | 2016 | 32 | 0.030 |
Why?
|
| NIH 3T3 Cells | 1 | 2016 | 111 | 0.030 |
Why?
|
| Cell Shape | 1 | 2016 | 51 | 0.030 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2015 | 27 | 0.030 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 1 | 2015 | 36 | 0.030 |
Why?
|
| Melanoma, Experimental | 1 | 2016 | 111 | 0.030 |
Why?
|
| Ribosomal Proteins | 1 | 2015 | 45 | 0.030 |
Why?
|
| Gossypol | 1 | 2014 | 5 | 0.030 |
Why?
|
| Recombinant Proteins | 2 | 2007 | 1015 | 0.030 |
Why?
|
| Rats | 2 | 2014 | 4059 | 0.030 |
Why?
|
| Risk Factors | 1 | 2005 | 5580 | 0.030 |
Why?
|
| DNA, Complementary | 1 | 2015 | 391 | 0.030 |
Why?
|
| Biocompatible Materials | 1 | 2016 | 198 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2015 | 110 | 0.030 |
Why?
|
| Temperature | 1 | 2016 | 414 | 0.030 |
Why?
|
| Subcutaneous Tissue | 1 | 2014 | 10 | 0.030 |
Why?
|
| Dependovirus | 1 | 2014 | 34 | 0.030 |
Why?
|
| Cell Aggregation | 1 | 2014 | 39 | 0.030 |
Why?
|
| Antigens, Viral, Tumor | 1 | 2014 | 15 | 0.030 |
Why?
|
| Glycogen | 1 | 2014 | 59 | 0.030 |
Why?
|
| Adenoviridae Infections | 1 | 2014 | 17 | 0.030 |
Why?
|
| Cytokines | 1 | 2018 | 813 | 0.030 |
Why?
|
| Odontoblasts | 1 | 2014 | 9 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 1 | 1994 | 270 | 0.030 |
Why?
|
| Cough | 1 | 1994 | 55 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 2013 | 3029 | 0.030 |
Why?
|
| S100 Calcium-Binding Protein A4 | 1 | 2013 | 4 | 0.030 |
Why?
|
| Maleimides | 1 | 2013 | 26 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2013 | 44 | 0.030 |
Why?
|
| Acetylation | 1 | 2014 | 141 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2016 | 361 | 0.030 |
Why?
|
| Homologous Recombination | 1 | 2014 | 53 | 0.030 |
Why?
|
| Lithium | 1 | 2013 | 62 | 0.030 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2013 | 137 | 0.030 |
Why?
|
| Subrenal Capsule Assay | 1 | 2013 | 5 | 0.030 |
Why?
|
| Neck Dissection | 1 | 1993 | 67 | 0.030 |
Why?
|
| Protein Stability | 1 | 2013 | 101 | 0.030 |
Why?
|
| Collagen Type I | 1 | 2013 | 73 | 0.030 |
Why?
|
| Physical Examination | 1 | 1994 | 150 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2014 | 520 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2015 | 179 | 0.030 |
Why?
|
| GTP-Binding Proteins | 1 | 2013 | 145 | 0.030 |
Why?
|
| Polyesters | 1 | 2013 | 42 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 493 | 0.030 |
Why?
|
| Intracranial Pressure | 1 | 1993 | 88 | 0.030 |
Why?
|
| Calcium Phosphates | 1 | 2013 | 78 | 0.030 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2013 | 87 | 0.030 |
Why?
|
| Lactic Acid | 1 | 2013 | 95 | 0.030 |
Why?
|
| Regeneration | 1 | 2014 | 151 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2016 | 469 | 0.030 |
Why?
|
| Estradiol | 1 | 2013 | 250 | 0.030 |
Why?
|
| Clinical Clerkship | 1 | 1994 | 118 | 0.030 |
Why?
|
| Estrogens | 1 | 2013 | 200 | 0.030 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2013 | 103 | 0.030 |
Why?
|
| PAX3 Transcription Factor | 1 | 2012 | 11 | 0.030 |
Why?
|
| Retinoid X Receptor alpha | 1 | 2012 | 7 | 0.030 |
Why?
|
| Paired Box Transcription Factors | 1 | 2012 | 52 | 0.020 |
Why?
|
| Pregnancy Proteins | 1 | 2012 | 37 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2018 | 2501 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2012 | 79 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2005 | 2369 | 0.020 |
Why?
|
| Polymers | 1 | 2013 | 199 | 0.020 |
Why?
|
| Indoles | 1 | 2013 | 306 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2012 | 162 | 0.020 |
Why?
|
| Perfusion | 1 | 2013 | 255 | 0.020 |
Why?
|
| Histones | 1 | 2014 | 344 | 0.020 |
Why?
|
| Antigens, Differentiation | 1 | 2012 | 141 | 0.020 |
Why?
|
| Interferon Type I | 1 | 2012 | 187 | 0.020 |
Why?
|
| Tetrazolium Salts | 1 | 2010 | 12 | 0.020 |
Why?
|
| Gentian Violet | 1 | 2010 | 10 | 0.020 |
Why?
|
| Colony-Forming Units Assay | 1 | 2010 | 41 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 4 | 1 | 2010 | 4 | 0.020 |
Why?
|
| Adolescent | 3 | 2010 | 9353 | 0.020 |
Why?
|
| Models, Animal | 1 | 2012 | 278 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2010 | 21 | 0.020 |
Why?
|
| Implants, Experimental | 1 | 2010 | 16 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2012 | 263 | 0.020 |
Why?
|
| Hypertrophy | 1 | 2010 | 67 | 0.020 |
Why?
|
| Activin Receptors, Type II | 1 | 2010 | 9 | 0.020 |
Why?
|
| Osseointegration | 1 | 2010 | 11 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2010 | 135 | 0.020 |
Why?
|
| RNA | 2 | 2004 | 587 | 0.020 |
Why?
|
| Limb Salvage | 1 | 2010 | 37 | 0.020 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2010 | 61 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 1994 | 1607 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2013 | 2076 | 0.020 |
Why?
|
| Nuclear Receptor Coactivator 1 | 1 | 2009 | 24 | 0.020 |
Why?
|
| Nuclear Receptor Co-Repressor 1 | 1 | 2009 | 24 | 0.020 |
Why?
|
| Epirubicin | 1 | 2009 | 14 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2010 | 269 | 0.020 |
Why?
|
| Ifosfamide | 1 | 2009 | 48 | 0.020 |
Why?
|
| Mass Screening | 1 | 1994 | 646 | 0.020 |
Why?
|
| Algorithms | 1 | 1998 | 1919 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2010 | 368 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2014 | 666 | 0.020 |
Why?
|
| Lipids | 1 | 2010 | 276 | 0.020 |
Why?
|
| Panax | 1 | 2010 | 170 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2010 | 342 | 0.020 |
Why?
|
| Necrosis | 1 | 2009 | 211 | 0.020 |
Why?
|
| Osteocalcin | 1 | 2008 | 26 | 0.020 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 2008 | 6 | 0.020 |
Why?
|
| RecQ Helicases | 1 | 2008 | 7 | 0.020 |
Why?
|
| Osteopontin | 1 | 2008 | 47 | 0.020 |
Why?
|
| Neurofibromatosis 2 | 1 | 2008 | 11 | 0.020 |
Why?
|
| Trephining | 1 | 1988 | 2 | 0.020 |
Why?
|
| Colonic Neoplasms | 2 | 2003 | 571 | 0.020 |
Why?
|
| Proto-Oncogenes | 1 | 2008 | 61 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2009 | 293 | 0.020 |
Why?
|
| Multiple Trauma | 1 | 1988 | 34 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2009 | 291 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2009 | 468 | 0.020 |
Why?
|
| Retinoblastoma Protein | 1 | 2008 | 64 | 0.020 |
Why?
|
| Radiography | 1 | 2010 | 809 | 0.020 |
Why?
|
| Torticollis | 1 | 1987 | 11 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2009 | 316 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2008 | 105 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2009 | 477 | 0.020 |
Why?
|
| Ligaments, Articular | 1 | 1987 | 40 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 866 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2010 | 1001 | 0.020 |
Why?
|
| Fracture Fixation, Internal | 1 | 1988 | 74 | 0.020 |
Why?
|
| Bone Morphogenetic Protein 3 | 1 | 2007 | 6 | 0.020 |
Why?
|
| Young Adult | 2 | 2010 | 6425 | 0.020 |
Why?
|
| North America | 1 | 2008 | 188 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2010 | 1170 | 0.020 |
Why?
|
| Helix-Loop-Helix Motifs | 1 | 2007 | 25 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2009 | 388 | 0.020 |
Why?
|
| DNA-Binding Proteins | 2 | 2004 | 1247 | 0.020 |
Why?
|
| Syndrome | 1 | 1987 | 452 | 0.020 |
Why?
|
| Genetic Techniques | 1 | 2007 | 73 | 0.020 |
Why?
|
| Adipocytes | 1 | 2008 | 166 | 0.020 |
Why?
|
| Snoring | 1 | 1986 | 12 | 0.020 |
Why?
|
| Cysteine-Rich Protein 61 | 1 | 2006 | 5 | 0.020 |
Why?
|
| Patient Selection | 1 | 2010 | 682 | 0.020 |
Why?
|
| Disease Progression | 1 | 2010 | 1485 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2006 | 52 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2006 | 137 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2008 | 419 | 0.020 |
Why?
|
| Luminescent Agents | 1 | 2005 | 6 | 0.020 |
Why?
|
| Wnt3 Protein | 1 | 2004 | 14 | 0.020 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2004 | 15 | 0.010 |
Why?
|
| Tendon Injuries | 1 | 2005 | 37 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2007 | 1240 | 0.010 |
Why?
|
| Binding Sites | 1 | 2007 | 1127 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2009 | 2033 | 0.010 |
Why?
|
| Desmin | 1 | 2003 | 10 | 0.010 |
Why?
|
| Myoglobin | 1 | 2003 | 29 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2010 | 1357 | 0.010 |
Why?
|
| Drug Administration Routes | 1 | 2003 | 19 | 0.010 |
Why?
|
| Collagen Type II | 1 | 2003 | 14 | 0.010 |
Why?
|
| SOX9 Transcription Factor | 1 | 2003 | 28 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2010 | 3273 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2005 | 470 | 0.010 |
Why?
|
| Bacteria | 1 | 2007 | 487 | 0.010 |
Why?
|
| Molecular Weight | 1 | 2002 | 332 | 0.010 |
Why?
|
| Bone Density | 1 | 2003 | 211 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2005 | 1499 | 0.010 |
Why?
|
| Sin3 Histone Deacetylase and Corepressor Complex | 1 | 2001 | 3 | 0.010 |
Why?
|
| Gentamicins | 1 | 2001 | 21 | 0.010 |
Why?
|
| Glutathione Transferase | 1 | 2001 | 112 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 1988 | 3692 | 0.010 |
Why?
|
| Actins | 1 | 2003 | 469 | 0.010 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2002 | 294 | 0.010 |
Why?
|
| Proteins | 1 | 2004 | 797 | 0.010 |
Why?
|
| Kinetics | 1 | 2001 | 1550 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2001 | 728 | 0.010 |
Why?
|
| Pseudotumor Cerebri | 1 | 1993 | 17 | 0.010 |
Why?
|
| Postoperative Care | 1 | 1993 | 234 | 0.010 |
Why?
|
| Palate | 1 | 1986 | 6 | 0.000 |
Why?
|
| Pharynx | 1 | 1986 | 44 | 0.000 |
Why?
|
| Sleep Apnea Syndromes | 1 | 1986 | 107 | 0.000 |
Why?
|